rs587776879
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_004656.4(BAP1):c.438-2A>G variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000657 in 152,140 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_004656.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BAP1 | NM_004656.4 | c.438-2A>G | splice_acceptor_variant, intron_variant | Intron 6 of 16 | ENST00000460680.6 | NP_004647.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152140Hom.: 0 Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152140Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74316
ClinVar
Submissions by phenotype
BAP1-related tumor predisposition syndrome Pathogenic:1
- -
not provided Pathogenic:1
- -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.438-2A>G intronic pathogenic mutation results from an A to G substitution two nucleotides upstream from coding exon 7 in the BAP1 gene. This nucleotide position is highly conserved in available vertebrate species. This alteration has been observed in individuals with a personal and/or family history that is consistent with BAP1-related disease (Testa JR et al. Nat Genet, 2011 Aug;43:1022-5). In vivo mouse studies have shown that mice with this alteration are significantly predisposed to BAP1-associated tumors (Kadariya Y et al. Cancer Res, 2016 05;76:2836-44). RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data; Testa JR et al. Nat Genet, 2011 Aug;43:1022-5). In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at